shIDO-ST / Tara I-O - LARVOL DELTA

Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. (PubMed, Cancer Gene Ther) - "Although increased tumor expression of IDO is associated with resistance to antibody therapy against programed cell death-1 (anti-PD1), co-administration of anti-PD1 with shIDO-ST did not provide additional tumor growth control in either model of colorectal cancer. Altogether, we demonstrate that treatment with shIDO-ST markedly delays tumor growth in two immunocompetent colorectal mouse models and this appears to be a superior therapeutic strategy compared to epacadostat or blocking anti-PD1 antibody therapy in colon cancer."

IO biomarker • Journal • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Immune Modulation • Inflammation • Solid Tumor • IFNG • TNFA

Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy. (PubMed, Biomedicines) - "These results suggest that the success of ICB therapy may be more accurately predicted by taking into account multiple factors such as potential for antigen presentation and immune subset repertoire in addition to markers already being considered. Alternatively, combination treatment with agents such as shIDO-ST could be used to create a more conducive tumor microenvironment for improving responses to ICB."

Checkpoint inhibition • Clinical • IO Biomarker • Journal • Immune Modulation • Inflammation • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Salmonella-Mediated Therapy Targeting Indoleamine 2, 3-Dioxygenase (IDO) Activates Innate Immunity and Mitigates Colorectal Cancer Growth (SSO 2019) - "An in vivo flank model was treated with:PBS (control), epacadostat (oral IDO inhibitor in trials), scrambled control-ST (shScr-ST) or shIDO-ST. IDO has a well-established immunosuppressive role in solid tumors. In this in vivo immunocompetent model of colorectal cancer, we demonstrate that treatment with shIDO-ST markedly delays tumor growth and is associated with an early influx of neutrophils and activation of the innate immune system. Further characterization of tumor infiltrating neutrophils is necessary to understand this mechanism of tumor growth inhibition."

IO Biomarker